Smartest Doc
Nanoparticle therapeutics for prostate cancer treatment
Maturitas, 08/17/2012
Clinical Article
Sanna V et al. – In particular, the combination of targeted and controlled–release polymer nanotechnologies has recently resulted in the clinical development of BIND–014, a promising targeted Docetaxel–loaded nanoprototype, which can be validated for use in the prostate cancer therapy. However, several limitations facing nanoparticle delivery to solid tumours, such as heterogeneity of intratumoural barriers and vasculature, cytotoxicity and/or hypersensitivity reactions to currently available cancer nanomedicines, and the difficult in developing targeted nanoparticles with optimal biophysicochemical properties, should be still addressed for a successful tumour eradication.